Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation
The novel coronavirus (SARS-CoV-2) pandemic, dubbed COVID-19, has become one of the most serious challenges for human populations in the vast majority of countries worldwide. Rapid spreading and increased mortality related to it required new approaches to manage epidemic processes on a global scale....
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
Sankt-Peterburg : NIIÈM imeni Pastera
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fcfffa1b852f42e083307cc3cd64bf93 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fcfffa1b852f42e083307cc3cd64bf93 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fcfffa1b852f42e083307cc3cd64bf932021-11-22T07:09:55ZFeatures of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation2220-76192313-739810.15789/2220-7619-FOD-1684https://doaj.org/article/fcfffa1b852f42e083307cc3cd64bf932021-03-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1684https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398The novel coronavirus (SARS-CoV-2) pandemic, dubbed COVID-19, has become one of the most serious challenges for human populations in the vast majority of countries worldwide. Rapid spreading and increased mortality related to it required new approaches to manage epidemic processes on a global scale. One of such approaches was based on analyzing SARS-CoV-2 seroprevalence associated with COVID-19. Our aim was to summarize the results on assessing seroprevalence to the SARS-CoV-2 nucleocapsid antigen (Nc) in residents from 26 regions of the Russian Federation, carried out during the first wave of the COVID-19 epidemic.Materials and methods. Seroprevalence distribution was examined in 26 model regions of the Russian Federation according to the unified method developed by the Rospotrebnadzor with the participation of the Federal State Institution Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Such approach implied formation of a group of volunteer subjects in model geographic region who were tested by ELISA for anti-Nc serum antibody level in peripheral blood. Analyzed primary data obtained in separate regions were either accepted for publication or released.Results. The current paper finalizes the data obtained in all 26 regions of the Russian Federation. The total SARS-CoV-2 seroprevalence was 19.5 (10.0–25.6)% with the maximum and minimum value found in the Kaliningrad Region and the Republic of Crimea, respectively (50.2% vs. 4.3%). A pattern of age-related seroprevalence distribution indicates insignificant predominance of seroprevalence among subjects of 1–17 years old: 22.1 (13.1–31.8)%. Among COVID-19 convalescents positive for SARS-CoV Nc antibodies it reached 60.0 (40.0–73.3)%. The number of contact persons comprised 6285 subjects or 8.5% of total volunteer cohort, with the level of seroprevalence reaching up to 25.3 (17.95–35.8)%. A direct correlation was revealed between levels of seroprevalence in convalescent and contact volunteers. In addition, the reproductive number for SARS-CoV was calculated comprising 5.8 (4.3–8.5) suggesting that one convalescent subject can infect at least 4 healthy individuals. A high level of asymptomatic forms of COVID-19 among seropositive subjects was confirmed empirically comprising up to 93.6 (87.1–94.9)%.Conclusion. A single cross-sectional study performed during 2020 June–August timeframe allowed to assess pattern of sex- and agerelated COVID-19 seroprevalence for general population in 26 Russian Federation regions. The data obtained may serve as a basis for the longitudinal cohort investigation with serial subject sampling. The timing and duration of study will be determined by dynamics of ongoing COVID-19 epidemic.A. Yu. PopovaE. E. AndreevaE. A. BaburaS. V. BalakhonovN. S. BashketovaM. V. BulanovN. N. ValeullinaD. V. GoryaevN. N. DetkovskayaE. B. EzhlovaN. N. ZaitsevaO. A. IstorikI. V. KovalchukD. N. KozlovskikhS. V. KombarovaO. P. KurganovaV. V. KutyrevA. E. LomovtsevL. A. LukichevaL. V. LyalinaA. A. MelnikovaO. M. MikailovaA. K. NoskovL. N. NoskovaE. E. OgleznevaT. P. OsmolovskayM. A. PatyashinaN. A. PenkovskayaL. V. SamoilovaV. S. SmirnovT. F. StepanovaO. E. TrotsenkoAreg A. TotolyanSankt-Peterburg : NIIÈM imeni Pasteraarticlecoronavirusesepidemic processcovid-19populationrussian federationterritory-related epidemic patternage-related pattern of epidemic processInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 11, Iss 2, Pp 297-323 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
coronaviruses epidemic process covid-19 population russian federation territory-related epidemic pattern age-related pattern of epidemic process Infectious and parasitic diseases RC109-216 |
| spellingShingle |
coronaviruses epidemic process covid-19 population russian federation territory-related epidemic pattern age-related pattern of epidemic process Infectious and parasitic diseases RC109-216 A. Yu. Popova E. E. Andreeva E. A. Babura S. V. Balakhonov N. S. Bashketova M. V. Bulanov N. N. Valeullina D. V. Goryaev N. N. Detkovskaya E. B. Ezhlova N. N. Zaitseva O. A. Istorik I. V. Kovalchuk D. N. Kozlovskikh S. V. Kombarova O. P. Kurganova V. V. Kutyrev A. E. Lomovtsev L. A. Lukicheva L. V. Lyalina A. A. Melnikova O. M. Mikailova A. K. Noskov L. N. Noskova E. E. Oglezneva T. P. Osmolovskay M. A. Patyashina N. A. Penkovskaya L. V. Samoilova V. S. Smirnov T. F. Stepanova O. E. Trotsenko Areg A. Totolyan Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation |
| description |
The novel coronavirus (SARS-CoV-2) pandemic, dubbed COVID-19, has become one of the most serious challenges for human populations in the vast majority of countries worldwide. Rapid spreading and increased mortality related to it required new approaches to manage epidemic processes on a global scale. One of such approaches was based on analyzing SARS-CoV-2 seroprevalence associated with COVID-19. Our aim was to summarize the results on assessing seroprevalence to the SARS-CoV-2 nucleocapsid antigen (Nc) in residents from 26 regions of the Russian Federation, carried out during the first wave of the COVID-19 epidemic.Materials and methods. Seroprevalence distribution was examined in 26 model regions of the Russian Federation according to the unified method developed by the Rospotrebnadzor with the participation of the Federal State Institution Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Such approach implied formation of a group of volunteer subjects in model geographic region who were tested by ELISA for anti-Nc serum antibody level in peripheral blood. Analyzed primary data obtained in separate regions were either accepted for publication or released.Results. The current paper finalizes the data obtained in all 26 regions of the Russian Federation. The total SARS-CoV-2 seroprevalence was 19.5 (10.0–25.6)% with the maximum and minimum value found in the Kaliningrad Region and the Republic of Crimea, respectively (50.2% vs. 4.3%). A pattern of age-related seroprevalence distribution indicates insignificant predominance of seroprevalence among subjects of 1–17 years old: 22.1 (13.1–31.8)%. Among COVID-19 convalescents positive for SARS-CoV Nc antibodies it reached 60.0 (40.0–73.3)%. The number of contact persons comprised 6285 subjects or 8.5% of total volunteer cohort, with the level of seroprevalence reaching up to 25.3 (17.95–35.8)%. A direct correlation was revealed between levels of seroprevalence in convalescent and contact volunteers. In addition, the reproductive number for SARS-CoV was calculated comprising 5.8 (4.3–8.5) suggesting that one convalescent subject can infect at least 4 healthy individuals. A high level of asymptomatic forms of COVID-19 among seropositive subjects was confirmed empirically comprising up to 93.6 (87.1–94.9)%.Conclusion. A single cross-sectional study performed during 2020 June–August timeframe allowed to assess pattern of sex- and agerelated COVID-19 seroprevalence for general population in 26 Russian Federation regions. The data obtained may serve as a basis for the longitudinal cohort investigation with serial subject sampling. The timing and duration of study will be determined by dynamics of ongoing COVID-19 epidemic. |
| format |
article |
| author |
A. Yu. Popova E. E. Andreeva E. A. Babura S. V. Balakhonov N. S. Bashketova M. V. Bulanov N. N. Valeullina D. V. Goryaev N. N. Detkovskaya E. B. Ezhlova N. N. Zaitseva O. A. Istorik I. V. Kovalchuk D. N. Kozlovskikh S. V. Kombarova O. P. Kurganova V. V. Kutyrev A. E. Lomovtsev L. A. Lukicheva L. V. Lyalina A. A. Melnikova O. M. Mikailova A. K. Noskov L. N. Noskova E. E. Oglezneva T. P. Osmolovskay M. A. Patyashina N. A. Penkovskaya L. V. Samoilova V. S. Smirnov T. F. Stepanova O. E. Trotsenko Areg A. Totolyan |
| author_facet |
A. Yu. Popova E. E. Andreeva E. A. Babura S. V. Balakhonov N. S. Bashketova M. V. Bulanov N. N. Valeullina D. V. Goryaev N. N. Detkovskaya E. B. Ezhlova N. N. Zaitseva O. A. Istorik I. V. Kovalchuk D. N. Kozlovskikh S. V. Kombarova O. P. Kurganova V. V. Kutyrev A. E. Lomovtsev L. A. Lukicheva L. V. Lyalina A. A. Melnikova O. M. Mikailova A. K. Noskov L. N. Noskova E. E. Oglezneva T. P. Osmolovskay M. A. Patyashina N. A. Penkovskaya L. V. Samoilova V. S. Smirnov T. F. Stepanova O. E. Trotsenko Areg A. Totolyan |
| author_sort |
A. Yu. Popova |
| title |
Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation |
| title_short |
Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation |
| title_full |
Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation |
| title_fullStr |
Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation |
| title_full_unstemmed |
Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation |
| title_sort |
features of developing sars-cov-2 nucleocapsid protein population-based seroprevalence during the first wave of the covid-19 epidemic in the russian federation |
| publisher |
Sankt-Peterburg : NIIÈM imeni Pastera |
| publishDate |
2021 |
| url |
https://doaj.org/article/fcfffa1b852f42e083307cc3cd64bf93 |
| work_keys_str_mv |
AT ayupopova featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT eeandreeva featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT eababura featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT svbalakhonov featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT nsbashketova featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT mvbulanov featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT nnvaleullina featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT dvgoryaev featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT nndetkovskaya featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT ebezhlova featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT nnzaitseva featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT oaistorik featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT ivkovalchuk featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT dnkozlovskikh featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT svkombarova featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT opkurganova featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT vvkutyrev featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT aelomovtsev featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT lalukicheva featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT lvlyalina featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT aamelnikova featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT ommikailova featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT aknoskov featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT lnnoskova featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT eeoglezneva featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT tposmolovskay featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT mapatyashina featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT napenkovskaya featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT lvsamoilova featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT vssmirnov featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT tfstepanova featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT oetrotsenko featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation AT aregatotolyan featuresofdevelopingsarscov2nucleocapsidproteinpopulationbasedseroprevalenceduringthefirstwaveofthecovid19epidemicintherussianfederation |
| _version_ |
1718417893329207296 |